STING1 and non-small cell lung carcinoma: However, some evidence, particularly in NSCLC and irradiated tumor models, suggests that STING activation may promote the recruitment of C-C chemokine receptor 2 (CCR2) -MDSCs, which possibly exacerbates immune tolerance after RT or STING agonist treatment [80].